Atıf İçin Kopyala
Herbst R. S., Giaccone G., de Marinis F., Reinmuth N., Vergnenegre A., Barrios C. H., ...Daha Fazla
NEW ENGLAND JOURNAL OF MEDICINE, cilt.383, sa.14, ss.1328-1339, 2020 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
383
Sayı:
14
-
Basım Tarihi:
2020
-
Doi Numarası:
10.1056/nejmoa1917346
-
Dergi Adı:
NEW ENGLAND JOURNAL OF MEDICINE
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Abstracts in Social Gerontology, AgeLine, BIOSIS, CAB Abstracts, Chemical Abstracts Core, CINAHL, Educational research abstracts (ERA), EMBASE, Food Science & Technology Abstracts, Gender Studies Database, International Pharmaceutical Abstracts, MEDLINE, MLA - Modern Language Association Database, Public Affairs Index, Veterinary Science Database
-
Sayfa Sayıları:
ss.1328-1339
-
İstanbul Üniversitesi Adresli:
Hayır
Özet
BackgroundThe efficacy and safety of the anti-programmed death ligand 1 (PD-L1) monoclonal antibody atezolizumab, as compared with those of platinum-based chemotherapy, as first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC) with PD-L1 expression are not known.